Bueno L, Fioramonti J, Hondé C, Fargeas M J, Primi M P
Gastroenterology. 1985 Feb;88(2):549-56. doi: 10.1016/0016-5085(85)90520-7.
The effects of two enkephalin analogues, (D-Ala2, Met5) and (D-Ala2, D-Leu5) enkephalinamide, on gastrointestinal and colonic motility were investigated in conscious fasted and fed dogs using chronically implanted strain gauges. The drugs, abbreviated here with the names DALAMIDE and DADLE, respectively, were administered by using both the intracerebroventricular and intravenous routes at increasing doses. In fasted dogs when administered via the intracerebroventricular route at a dose of 20 ng X kg-1, DALAMIDE disrupted the migrating myoelectric complex pattern. A similar effect was obtained only with a dose 25 times higher (500 ng X kg-1) administered intravenously; at this dosage DALAMIDE administered intravenously also reduced the colonic motility index by 66%. When intracerebroventricularly administered in fed dogs, 2 h after a meal, DALAMIDE (20 ng X kg-1) inhibited gastric motility but restored the jejunal migrating myoelectric complex pattern as "ectopic" complexes for 4-6 h. This effect however was not reproduced by intravenous treatment even at the highest dose used (500 ng X kg-1). Both intracerebroventricular and intravenous administration of DADLE, at doses as high as 100 and 500 ng X kg-1, respectively, affected neither the motility pattern nor the motility index of the antrum and proximal jejunum in the fasted or fed state. However, intracerebroventricular, but not intravenous, administration produced a short (10-15 min) increase of colonic motility. These results suggest that (a) Met-enkephalin influences the gastrointestinal motility predominately by a central action, manifested as a migrating myoelectric complex "reorganizing" effect in fed dogs; (b) Leu-enkephalin exerts a predominately centrally mediated stimulation of colonic motility, whereas Met-enkephalin inhibits it probably by a peripheral mechanism.
使用慢性植入的应变片,在清醒的禁食和进食犬中研究了两种脑啡肽类似物,即(D-丙氨酸²,甲硫氨酸⁵)脑啡肽和(D-丙氨酸²,D-亮氨酸⁵)脑啡肽酰胺对胃肠和结肠运动的影响。这两种药物在此分别简称为DALAMIDE和DADLE,通过脑室内和静脉内途径以递增剂量给药。在禁食犬中,当通过脑室内途径以20 ng·kg⁻¹的剂量给药时,DALAMIDE破坏了移行性肌电复合波模式。仅静脉内给予高25倍(500 ng·kg⁻¹)的剂量时才获得类似效果;在此剂量下,静脉内给予DALAMIDE也使结肠运动指数降低了66%。在进食犬进食后2小时通过脑室内给药时,DALAMIDE(20 ng·kg⁻¹)抑制胃运动,但在4 - 6小时内将空肠移行性肌电复合波模式恢复为“异位”复合波。然而,即使使用最高剂量(500 ng·kg⁻¹)进行静脉治疗也未重现这种效果。分别以高达100和500 ng·kg⁻¹的剂量对DADLE进行脑室内和静脉内给药,在禁食或进食状态下均未影响胃窦和空肠近端的运动模式及运动指数。然而,脑室内给药而非静脉内给药会使结肠运动短暂增加(10 - 15分钟)。这些结果表明:(a)甲硫氨酸脑啡肽主要通过中枢作用影响胃肠运动,在进食犬中表现为移行性肌电复合波“重组”效应;(b)亮氨酸脑啡肽主要通过中枢介导刺激结肠运动,而甲硫氨酸脑啡肽可能通过外周机制抑制结肠运动。